AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16914336
Drug: FSC 500/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSC 500/50 microg Diskus, 1 inhalation twice daily + tiotropium 18 microg Handihaler, 1 inhalation once daily
Trial: 9711449
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg/day
Trial: 11358726
Drug: Combined regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined regimen (cetirizine, clarythromycin, topical corticosteroids, hydrating preparations)
Trial: 9145693
Drug: Ophthalmic fluorometholone-gentamicin
RxNorm normalized name: fluorometholone Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic fluorometholone-gentamicin
Trial: 9145693
Drug: Ophthalmic betamethasone-gentamicin
RxNorm normalized name: betamethasone / gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic betamethasone-gentamicin
Trial: 3064776
Drug: Adjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant systemic treatment alone (chemotherapy and/or tamoxifen)
Trial: 3101849
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment alone (Control)
Trial: 31895881
Drug: wSp 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wSp 0.1 mg
Trial: 31895881
Drug: wSp 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wSp 0.3 mg
Trial: 31895881
Drug: wSp 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wSp 0.6 mg
Trial: 24314016
Drug: Oral prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prophylaxis with tongue cleaning
Trial: 23013513
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of simvastatin and ezetimibe
Trial: 12923133
Drug: CDB-2914 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDB-2914 at doses of 1-100 mg
Trial: 12923133
Drug: CDB-2914 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDB-2914 at 200 mg
Trial: 12923133
Drug: CDB-2914 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDB-2914 at doses of 10, 50, 100 and 200 mg
Trial: 12212206
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg.d-1
Trial: 20876317
Drug: Preoperative chemoradiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiotherapy followed by postoperative chemotherapy
Trial: 18361816
Drug: Block +
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Block + manipulation treatment (Group I)
Trial: 10994616
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d. for 2 weeks
Trial: 8772566
Drug: Episodic GHRH
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Episodic GHRH administration (200 micrograms, 4 boluses of 50 micrograms each at 2200, 2300, 2400, and 0100 h)
Trial: 8772566
Drug: Continuous GHRH
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous GHRH infusion (57 micrograms/h between 2130 and 0100 h)
Trial: 3158254
Drug: Atracurium steady-state
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium steady-state infusion during halothane or isoflurane anesthesia
Trial: 3158254
Drug: Atracurium steady-state
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium steady-state infusion during balanced anesthesia
Trial: 26673811
Drug: Ibrutinib (560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (560 mg daily)
Trial: 26673811
Drug: Temsirolimus (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus (175 mg on days 1, 8, and 15 of cycle 1; 75 mg on days 1, 8, and 15 of subsequent cycles)
Trial: 18522727
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of cognac (1.2 +/- 0.1 dl)
Trial: 18522727
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of cognac (2.4 +/- 0.3 dl)
Trial: 10050702
Drug: enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enoxaparin (40 mg, 4000 anti-Xa IU)
Trial: 7486040
Drug: Thiamylal (4.0‐5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamylal (4.0‐5.0 mg/kg)
Trial: 7486040
Drug: Ketamine (1.5‐2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (1.5‐2.0 mg/kg)
Trial: 7486040
Drug: Succinylcholine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (1.0 mg/kg) - Control Group O
Trial: 2077498
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chloral hydrate and hydroxyzine (placebo control)
Trial: 2077498
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate (three doses)
Trial: 6778329
Drug: Antihistamine-adrenergic combination
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine-adrenergic combination (diphenhydramine and pseudoephedrine)
Trial: 25541338
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid 1.5 g in povidone-iodine solution (group B)
Trial: 25541338
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid 3.0 g in povidone-iodine solution (group C)
Trial: 25541338
Drug: Povidone-iodine solution
RxNorm normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine solution (control: group A)
Trial: 19203565
Drug: Clarithromycin (CLR)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin (CLR) 500 mg oral dose (Group 1: Merck; Group 2: Klaricid)
Trial: 17381500
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (twice daily)
Trial: 8068588
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of metronidazole three times daily for 5 days
Trial: 8068588
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of metronidazole twice daily for 5 days
Trial: 31126306
Drug: Creatine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine and electrolyte formulated multi‐ingredient performance supplement (MIPS)
Trial: 24495636
Drug: Pressure therapy
RxNorm normalized name: AerobiKA Oscillating Positive Expiratory Pressure Therapy System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure therapy (PT)
Trial: 18632424
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg per day for nine days, starting 48 hours before CPB, with an additional dose of 40 mg one hour after surgery
Trial: 3514224
Drug: N 10
RxNorm normalized name: DYN 101
DrugBank: DYN-101 (DB17921)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N 10 mg six times daily
Trial: 3514224
Drug: V 80
RxNorm normalized name: omidubicel-onlv 8000000 CELLS/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V 80 mg three times daily
Trial: 3514224
Drug: ISDN 10
RxNorm normalized name: ISDN 10 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN 10 mg six times daily
Trial: 3514224
Drug: N 20
RxNorm normalized name: Span 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N 20 mg six times daily
Trial: 3514224
Drug: V 120
RxNorm normalized name: VYALEV 120 MG / 2400 MG in 10 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V 120 mg four times daily
Trial: 3514224
Drug: ISDN 20
RxNorm normalized name: ISDN 20 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN 20 mg six times daily
Trial: 3514224
Drug: N r
RxNorm normalized name: HumuLIN R
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N r 20 mg four times daily
Trial: 3514224
Drug: V r
RxNorm normalized name: HIV receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V r 120 mg three times daily
Trial: 3514224
Drug: ISDN sr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN sr 40 mg four times daily
Trial: 26230902
Drug: PDX/GOS (formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDX/GOS (formula with 4 g/L of PDX/GOS)
Trial: 22378725
Drug: Capsinoids (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsinoids (9 mg)
Trial: 30567753
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HD-MTX)
Trial: 20125159
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HD-MTX) and high-dose cytarabine (HD-AraC)
Trial: 17347177
Drug: Gentamicin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (7.5 mg/kg, intramuscular, once daily)
Trial: 10584136
Drug: Amifostine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (500 mg, day 1 to 5 and 29 to 33) during concurrent radio-chemotherapy with carboplatin (70 mg/m2, day 1 to 5 and 29 to 33)
Trial: 1988577
Drug: FEC 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC 50 (5FU 500 mg/m2, cyclophosphamide 500 mg/m2, epirubicin 50 mg/m2)
Trial: 1988577
Drug: FEC 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC 75 (5FU 500 mg/m2, cyclophosphamide 500 mg/m2, epirubicin 75 mg/m2)
Trial: 1988577
Drug: Epirubicin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin alone (75 mg/m2)
Trial: 24515544
Drug: Cystoscopic onabotulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cystoscopic onabotulinum toxin A injection and oral placebo medication
Trial: 24515544
Drug: Cystoscopic placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cystoscopic placebo injection and active oral medication
Trial: 12119202
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg per day)
Trial: 9854759
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment of six ineffective exercises
Trial: 2142237
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg toremifene daily for 7 days
Trial: 2142237
Drug: 68 mg
RxNorm normalized name: pyrantel 68 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68 mg toremifene for 5 days
Trial: 2142237
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg tamoxifen for 5 days
Trial: 31999175
Drug: Telephone-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based intervention (4 weekly calls + 5 biweekly calls)
Trial: 31274183
Drug: High-dose Sandostatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Sandostatin LAR monotherapy (40 mg)
Trial: 31274183
Drug: High-dose Sandostatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Sandostatin LAR plus pegvisomant
Trial: 31274183
Drug: High-dose Sandostatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Sandostatin LAR plus cabergoline
Trial: 31274183
Drug: High-dose Sandostatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Sandostatin LAR monotherapy
Trial: 31274183
Drug: High-dose Sandostatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Sandostatin LAR (all groups)
Trial: 31274183
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (including combinations)
Trial: 27067612
Drug: Myofascial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial therapy protocol (21 minutes)
Trial: 24338522
Drug: Generic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic medication switches
Trial: 24338522
Drug: Confusion due
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Confusion due to medication changes
Trial: 24338522
Drug: No problems
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No problems with medication changes
Trial: 23166441
Drug: Exenatide once
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide once weekly and twice daily
Trial: 17553207
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg intravenously every 3 months
Trial: 15541406
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg vitamin E daily
Trial: 15541406
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg aspirin daily
Trial: 15541406
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vitamin E and low-dose aspirin
Trial: 10945509
Drug: Olopatadine hydrochloride
RxNorm normalized name: Olopatadine Hydrochloride
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine hydrochloride 0.1% ophthalmic solution
Trial: 11558863
Drug: Azelastine hydrochloride
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine hydrochloride 0.05% ophthalmic solution
Trial: 9156269
Drug: Tetanus toxoid
RxNorm normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus toxoid (TT) vaccine at 6, 8 and 14 months after BMT (early group, n = 23)
Trial: 9156269
Drug: Tetanus toxoid
RxNorm normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus toxoid (TT) vaccine at 18, 20 and 26 months after BMT (late group, n = 22)
Trial: 9156269
Drug: Tetanus toxoid
RxNorm normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus toxoid (TT) vaccine (both groups)
Trial: 9156269
Drug: Tetanus toxoid
RxNorm normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus toxoid (TT) vaccine (late group)
Trial: 23322362
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 μg/d)
Trial: 29024120
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg once/6 months)
Trial: 27146000
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 1.6104 CFU of WRSS1 vaccine
Trial: 25608849
Drug: AG‐dieckol (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG‐dieckol (1500 mg per day)
Trial: 21040534
Drug: Screening program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening program for Q fever with immediate analysis of blood samples for IgG and IgM antibodies using a cut-off level of 1:32.
Trial: 9583341
Drug: Complete cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete cognitive-behavioral therapy (CT)
Trial: 2539762
Drug: Quinapril 10
RxNorm normalized name: quinapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 10 mg once daily
Trial: 2539762
Drug: Quinapril 5
RxNorm normalized name: quinapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 5 mg once daily
Trial: 2539762
Drug: Quinapril administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril administered once or twice daily
Trial: 335790
Drug: L-tryptophan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (6 g daily) with unilateral ECT
Trial: 24068631
Drug: Fenofibrate (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (160 mg/day for 6 weeks)
Trial: 24068631
Drug: ER-niacin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER-niacin (0.5 g/day for 3 weeks, then 1 g/day for 6 weeks)
Trial: 21378388
Drug: Troponin I
RxNorm normalized name: Troponin I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin I (TnI) assessment at 24 hours (> 6.6 μg/l)
Trial: 15472216
Drug: rhGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH treatment (6 mg/d) for 3 months
Trial: 11721171
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (anthracycline-based) for TCRBCL patients
Trial: 11721171
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (anthracycline-based) for DLBCL patients
Trial: 31375440
Drug: 7.5mcg or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5mcg or 15mcg of hemagglutinin (HA)/dose for children 6-35 months; 15mcg HA/dose for children 3-17 years, administered via intramuscular injection, two doses 21 days apart.
Trial: 31375440
Drug: H3N2v vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3N2v vaccine
Trial: 28124817
Drug: Once-weekly titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly titration of IDegLira (based on mean of 2 pre-breakfast PG readings)
Trial: 28124817
Drug: Twice-weekly titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly titration of IDegLira (based on mean of 3 pre-breakfast PG readings)
Trial: 26106626
Drug: 40 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 μg/d vitamin D3
Trial: 26106626
Drug: 80 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 μg/d vitamin D3
Trial: 19964412
Drug: Combined treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatments (STN DBS + medication)
Trial: 19964412
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (mof-sof)
Trial: 17242254
Drug: Chemoradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation therapy (standardized 5-week course)
Trial: 15494583
Drug: Standardized dose‐matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized dose‐matched therapeutic exercises (DMTE)
Trial: 11448094
Drug: Haloperidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (1 mg i.v.)
Trial: 11448094
Drug: Chlorpromazine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (100 mg p.o.)
Trial: 11448094
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg p.o.)
Trial: 11448094
Drug: Lorazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (2 mg p.o.)
Trial: 9506206
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (Gamimune N)
Trial: 2463035
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) (Fragmin) 2500 anti-factor Xa units twice daily for 7 days
Trial: 2463035
Drug: Dextran 70
RxNorm normalized name: Dextran 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran 70 (Macrodex) 500 ml twice during the day of operation, followed by a single infusion of 500 ml on the first and again on the third postoperative day
Trial: 27285306
Drug: Combined hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormonal pills (CHP)
Trial: 1345694
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion (10 mcg/kg.min for 1 hour)
Trial: 1345694
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus dobutamine (D+) for 9 consecutive days
Trial: 1345694
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy only (D-)
Trial: 3877290
Drug: Propofol ('Diprivan')
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol ('Diprivan') 1.5 mg/kg
Trial: 12712780
Drug: Thiopentone 2
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 2 mg/kg
Trial: 16093575
Drug: Troglitazone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (400 mg daily for eight weeks)
Trial: 12814141
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (up to 3100 microg)